Drug General Information |
Drug ID |
D0D9TU
|
Former ID |
DNC004115
|
Drug Name |
LAVENDUSTIN A
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C21H19NO6
|
Canonical SMILES |
C1=CC=C(C(=C1)CN(CC2=C(C=CC(=C2)O)O)C3=CC(=C(C=C3)O)C(=<br />O)O)O
|
InChI |
1S/C21H19NO6/c23-16-6-8-19(25)14(9-16)12-22(11-13-3-1-2-4-18(13)24)15-5-7-20(26)17(10-15)21(27)28/h1-10,23-26H,11-12H2,(H,27,28)
|
InChIKey |
ULTTYPMRMMDONC-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Epidermal growth factor receptor |
Target Info |
Inhibitor |
[1]
|
Lck tyrosine kinase |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
MAPK signaling pathway
|
ErbB signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
Cytokine-cytokine receptor interaction
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
Endocytosis
|
PI3K-Akt signaling pathway
|
Dorso-ventral axis formation
|
Focal adhesion
|
Adherens junction
|
Gap junction
|
Regulation of actin cytoskeleton
|
GnRH signaling pathway
|
Estrogen signaling pathway
|
Oxytocin signaling pathway
|
Epithelial cell signaling in Helicobacter pylori infection
|
Hepatitis C
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Pancreatic cancer
|
Endometrial cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Bladder cancer
|
Non-small cell lung cancer
|
Central carbon metabolism in cancer
|
Choline metabolism in cancerhsa04064:NF-kappa B signaling pathway
|
Osteoclast differentiation
|
Natural killer cell mediated cytotoxicity
|
T cell receptor signaling pathway
|
HTLV-I infection
|
Primary immunodeficiency
|
NetPath Pathway
|
IL4 Signaling Pathway
|
EGFR1 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Cadherin signaling pathway
|
EGF receptor signaling pathwayP00049:Parkinson disease
|
T cell activation
|
Pathway Interaction Database
|
LPA receptor mediated events
|
Signaling events mediated by PTP1B
|
Arf6 signaling events
|
Signaling events mediated by TCPTP
|
Thromboxane A2 receptor signaling
|
SHP2 signaling
|
Regulation of Telomerase
|
EGF receptor (ErbB1) signaling pathway
|
EGFR-dependent Endothelin signaling events
|
Posttranslational regulation of adherens junction stability and dissassembly
|
Direct p53 effectors
|
ErbB1 downstream signaling
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
E-cadherin signaling in keratinocytes
|
ErbB receptor signaling network
|
Internalization of ErbB1
|
Stabilization and expansion of the E-cadherin adherens junction
|
a6b1 and a6b4 Integrin signaling
|
Syndecan-3-mediated signaling eventsnfkappabatypicalpathway:Atypical NF-kappaB pathway
|
Glypican 1 network
|
TCR signaling in naï
|
IL12-mediated signaling events
|
Regulation of p38-alpha and p38-beta
|
TCR signaling in naï
|
IL2-mediated signaling events
|
CXCR4-mediated signaling events
|
Class I PI3K signaling events
|
IL2 signaling events mediated by PI3K
|
amb2 Integrin signaling
|
EPHA forward signaling
|
PDGFR-beta signaling pathway
|
IL2 signaling events mediated by STAT5
|
Ephrin B reverse signaling
|
Alpha-synuclein signaling
|
Reactome
|
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
SHC1 events in ERBB2 signaling
|
PLCG1 events in ERBB2 signaling
|
PIP3 activates AKT signaling
|
GRB2 events in EGFR signaling
|
GAB1 signalosome
|
SHC1 events in EGFR signaling
|
EGFR downregulation
|
GRB2 events in ERBB2 signaling
|
PI3K events in ERBB2 signaling
|
EGFR Transactivation by Gastrin
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
Constitutive Signaling by EGFRvIII
|
RAF/MAP kinase cascadeR-HSA-114604:GPVI-mediated activation cascade
|
Regulation of KIT signaling
|
Phosphorylation of CD3 and TCR zeta chains
|
Translocation of ZAP-70 to Immunological synapse
|
Generation of second messenger molecules
|
PECAM1 interactions
|
DAP12 signaling
|
CD28 co-stimulation
|
CD28 dependent PI3K/Akt signaling
|
CD28 dependent Vav1 pathway
|
CTLA4 inhibitory signaling
|
PD-1 signaling
|
Interleukin-2 signaling
|
WikiPathways
|
ErbB Signaling Pathway
|
Regulation of Actin Cytoskeleton
|
EGF/EGFR Signaling Pathway
|
MAPK Signaling Pathway
|
Focal Adhesion
|
Aryl Hydrocarbon Receptor Pathway
|
Extracellular vesicle-mediated signaling in recipient cells
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
Bladder Cancer
|
Hair Follicle Development: Induction (Part 1 of 3)
|
Signaling by ERBB4
|
Signaling by ERBB2
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
PIP3 activates AKT signaling
|
Nanoparticle-mediated activation of receptor signaling
|
Aryl Hydrocarbon Receptor
|
Spinal Cord Injury
|
Integrated Pancreatic Cancer Pathway
|
Gastric cancer network 2
|
AGE/RAGE pathway
|
Signaling Pathways in Glioblastoma
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
Integrated Breast Cancer Pathway
|
Signaling by EGFR
|
L1CAM interactionsWP61:Notch Signaling Pathway
|
Interferon type I signaling pathways
|
IL-2 Signaling Pathway
|
Inflammatory Response Pathway
|
Signaling by SCF-KIT
|
DAP12 interactions
|
Host Interactions of HIV factors
|
T-Cell Receptor and Co-stimulatory Signaling
|
B Cell Receptor Signaling Pathway
|
TSLP Signaling Pathway
|
TCR signaling
|
Costimulation by the CD28 family
|
References |
REF 1 | J Med Chem. 1994 Nov 25;37(24):4079-84.Novel antiproliferative agents derived from lavendustin A. |
---|
REF 2 | J Med Chem. 1993 Oct 1;36(20):3010-4.Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. |